563 related articles for article (PubMed ID: 22454413)
21. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
[TBL] [Abstract][Full Text] [Related]
22. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
[TBL] [Abstract][Full Text] [Related]
23. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
[TBL] [Abstract][Full Text] [Related]
24. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
25. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
[TBL] [Abstract][Full Text] [Related]
26. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
[TBL] [Abstract][Full Text] [Related]
27. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract][Full Text] [Related]
28. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
Schmitt-Ney M; Camussi G
PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.
Davicioni E; Anderson JR; Buckley JD; Meyer WH; Triche TJ
J Clin Oncol; 2010 Mar; 28(7):1240-6. PubMed ID: 20124188
[TBL] [Abstract][Full Text] [Related]
30. Molecular biology of rhabdomyosarcoma.
Gallego Melcón S; Sánchez de Toledo Codina J
Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
[TBL] [Abstract][Full Text] [Related]
31. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
32. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue.
Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718
[TBL] [Abstract][Full Text] [Related]
33. Uncovering metabolism in rhabdomyosarcoma.
Monti E; Fanzani A
Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235
[TBL] [Abstract][Full Text] [Related]
34. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
35. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
37. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
38. PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells.
Yoshida H; Miyachi M; Sakamoto K; Ouchi K; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Imamura T; Iehara T; Kakazu N; Hojo H; Hosoi H
Oncogene; 2014 Dec; 33(49):5601-8. PubMed ID: 24213582
[TBL] [Abstract][Full Text] [Related]
39. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
Makawita S; Ho M; Durbin AD; Thorner PS; Malkin D; Somers GR
Pediatr Dev Pathol; 2009; 12(2):127-35. PubMed ID: 18788888
[TBL] [Abstract][Full Text] [Related]
40. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
